Biolegend, 329918, PE/Cyanine7 anti-human CD279 (PD-1) Antibody, 100tests

Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.
100tests
Verified Reactivity: Human
Reported Reactivity: African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type: Monoclonal
Host Species: Mouse
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes: Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Application References(PubMed link indicates BioLegend citation): Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA) Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA) Velu V, et al. 2007. J. Virol. 81:5819. (FA) Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA) Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity) Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC) Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG) Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Bettini E, et al. 2022. STAR Protoc. 3:101840. PubMed Wenthe J, et al. 2021. Cancer Immunology Immunotherapy. . PubMed Zhou J, et al. 2020. Oncol Lett. 1.336111111. PubMed Mylvaganam G, et al. 2014. J Immunol. 193:4527. PubMed Amancha P, et al. 2013. J Immunol. 191:6060. PubMed Policicchio B, et al. 2016. PLoS Pathog. 12: 1005879. PubMed Yoshitomi H, et al. 2018. Nat Commun. 2.9875. PubMed Hong J, et al. 2012. J Immunol. 188:3247. PubMed Wildner NH, et al. 2022. Front Immunol. 13:886646. PubMed Olwenyi OA, et al. 2020. Cells. 9:. PubMed McLane LM, et al. 2021. Cell Reports. 35(6):109120. PubMed Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed Wang M, et al. 2022. Immun Inflamm Dis. 10:e626. PubMed Tauriainen J, et al. 2017. Sci Rep. 7:40354. PubMed Au L, et al. 2021. Cancer Cell. 39:1497. PubMed Hong J, et al. 2014. J Immunol. 193:797. PubMed Colleen S McGary et al. 2017. Immunity. 47(4):776-788 . PubMed Verma A, et al. 2021. Cell Rep. 37:109942. PubMed Tardif V, et al. 2019. Nat Commun. 10:823. PubMed Dart SJ, et al. 2021. Sci Rep. 11:15312. PubMed Khanam A, et al. 2021. Front Immunol. 11:599648. PubMed Edwards CJ, et al. 2021. Br J Cancer. . PubMed Hsu H, et al. 2016. J Immunol. 197: 1884 - 1892. PubMed Lee J, et al. 2020. Sci Rep. 10:17753. PubMed Punik J, et al. 2021. Cell Reports. 35(13):109320. PubMed Kuo HH, et al. 2018. Immunity. 48:1183. PubMed Ohue Y, et al. 2014. Clin Cancer Res. 20:5052. PubMed van Montfoort N, et al. 2018. Cell. 175:1744. PubMed Gordon-Alonso M,et al. 2017. Nat. Commun. 10.1038/s41467-017-00925-6. PubMed Parsons E, et al. 2016. PLoS One. 11:e0167841. PubMed Shen C, et al. 2021. Front Immunol. 12:680055. PubMed Beltra JC, et al. 2020. Immunity. 52(5):825-841. PubMed Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed Den Braanker H, et al. 2021. Front Immunol. 12:768113. PubMed Barili V, et al. 2020. Nat Commun. 0.877777778. PubMed Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed Dehmani S, et al. 2021. Front Immunol. 12:732530. PubMed Volpin V, et al. 2020. Cancer Immunol Res. 8:1163. PubMed Chen Y, et al. 2020. Cell. 1496:183. PubMed Brudno JN, et al. 2020. Nat Med. 270:26. PubMed Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed Lederer K, et al. 2022. Cell. . PubMed Chellappa S, et al. 2019. J Immunol. 202:1397. PubMed Duhen R, et al. 2021. Nat Commun. 12:1047. PubMed Rnjak D, et al. 2021. Transfus Clin Biol. . PubMed Csomós K, et al. 2022. Nat Immunol. 23:1256. PubMed Beyer M, et al. 2016. Nat Immunol. 17:593-603. PubMed Diamantopoulos PT, et al. 2022. Cancers (Basel). 14:. PubMed Hu JQ, et al. 2020. J Cancer. 3.409722222. PubMed Tang X, et al. 2020. Sci Adv. 6:eaaz0374. PubMed
RRID: AB_2159325 (BioLegend Cat. No. 329917) AB_2159324 (BioLegend Cat. No. 329918)
Structure: Immunoglobulin superfamily
Distribution: Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells
Ligand/Receptor: B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type: B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area: Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family: CD Molecules, Immune Checkpoint Receptors
Gene ID: 5133
UniProt: View information about CD279 on UniProt.org
Clone: EH12.2H7
Regulatory Status: RUO
Other Names: PD-1, PDCD1
Isotype: Mouse IgG1, κ